Cargando...
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival (OS) in untreated fit patients; humanized ant...
Gardado en:
| Publicado en: | Pharmgenomics Pers Med |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4325625/ https://ncbi.nlm.nih.gov/pubmed/25691812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S55501 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|